Department of Pharmaceutical Chemistry, Istanbul University, Beyazıt 34116, Istanbul, Turkey.
Mol Divers. 2012 Aug;16(3):525-39. doi: 10.1007/s11030-012-9385-y. Epub 2012 Aug 15.
A new series of 5-fluoro-N(2)-(cyclohexylidene)-3-phenyl-1H-indole-2-carbohydrazides (6a-6e) and their cyclization products 5-fluoro-N-(3-oxo-1-thia-4-azaspiro [4.5]dec-4-yl)-3-phenyl-1H-indole-2-carboxamides (7a-7e, 8a-8e) have been synthesized and evaluated for in vitro antimycobacterial activity against Mycobacterium tuberculosis H37Rv using the Microplate Alamar Blue Assay (MABA). Compounds showed moderate to good inhibitory activity at 6.25 μg/mL. Among them, 7b, 7d, 8b, and 8d were the most potent analogs with an inhibition range of 91-95 %. Additionally, compounds 6a, 7a, 7e, 8a, and 8e were subjected to the National Cancer Institute's (NCI) in vitro disease-oriented antitumor screening to be evaluated for antitumor activity. 8e, the most potent compound examined, displayed broad spectrum antiproliferative activity with particular selectivity against four leukemia cell lines (CCRF-CEM, HL-60 (TB), K-562, and RPMI-8226) with log (10) GI (50) values between -5.68 and -6.09.
一系列新的 5-氟-N(2)-(环己基亚基)-3-苯基-1H-吲哚-2-甲酰胺（6a-6e）及其环化产物 5-氟-N-(3-氧代-1-硫杂-4-氮杂螺[4.5]癸-4-基)-3-苯基-1H-吲哚-2-甲酰胺（7a-7e，8a-8e）已经被合成并通过微板 Alamar Blue 测定法（MABA）评估了它们对结核分枝杆菌 H37Rv 的体外抗分枝杆菌活性。化合物在 6.25 μg/mL 时显示出中等至良好的抑制活性。其中，7b、7d、8b 和 8d 是最有效的类似物，抑制范围为 91-95%。此外，化合物 6a、7a、7e、8a 和 8e 被国家癌症研究所（NCI）进行了体外疾病定向抗肿瘤筛选，以评估其抗肿瘤活性。8e 是研究的最有效化合物，对四种白血病细胞系（CCRF-CEM、HL-60（TB）、K-562 和 RPMI-8226）具有广谱抗增殖活性，其对数（10）GI（50）值在-5.68 到-6.09 之间。
